Abstract: The present invention features a configurable self-massaging device. In some embodiments, the device may comprise a base component having a leg support pole extending from the base component at an angle. The device may further comprise a main pole extending vertically from the base component. The device may further comprise one or more massage components. Each massage component may comprise a cushion, a vibration component attached to the cushion, wherein actuating the vibration component may cause vibration of the cushion, and an attachment component configured to secure the massage component to a point on a pole. A massage component attached to the main pole may allow for massaging of a user's hands, wrists, back, buttocks, chest, face, neck, and head. A massage component attached to the leg support pole may allow for massaging of a user's legs and feet.

Abstract: A configurable self-massaging device. The device may comprise a base component having a leg support pole extending from the base component at an angle. The device may further comprise a main pole extending vertically from the base component. The device may further comprise one or more massage components. Each massage component may comprise a cushion, a vibration component attached to the cushion, wherein actuating the vibration component may cause vibration of the cushion, and an attachment component configured to secure the massage component to a point on a pole. A massage component attached to the main pole may allow for massaging of a user's hands, wrists, back, buttocks, chest, face, neck, and head. A massage component attached to the leg support pole may allow for massaging of a user's legs and feet.

Abstract: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof and at least one antidiabetic agent.

Abstract: The present invention relates to a combination of organic compounds, a pharmaceutical composition and a kit of parts comprising said combination of organic compounds and to a method of treatment or prevention of certain conditions or diseases.

Abstract: The invention relates to a method of inhibiting platelet aggregation comprising administering a therapeutically effective amount of an ARB or its metabolite, especially Valsartan or its metabolite valeryl 4-hydroxy valsartan. Conditions to be treated by inhibition of platelet aggregation include acute myocardial infarction, ischemic stroke, angina pectoris, acute coronary syndromes, TIA (transient ischemic attacks, or acute cerebrovascular syndromes), heart failure, chest pain of ischemic etiology, syndrome X, thromboembolism, pulmonary hypertension, diabetes mellitus, peripheral vascular disease, deep vein thrombosis, arterial thrombosis of any vessel, catheter thrombotic occlusion or reocclusion.

Abstract: The invention relates to a pharmaceutical composition comprising (i) a renin inhibitor, (ii) a calcium channel blocker (CCB), and (iii) a diuretic and to a method of treatment of a condition or a disease selected from the group consisting of hypertension, heart failure such as (acute and chronic) congestive heart failure, left ventricular dysfunction and hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction and its sequelae, atherosclerosis, angina (whether unstable or stable), renal insufficiency (diabetic and non-diabetic), heart failure, angina pectoris, diabetes, secondary aldosteronism, primary and secondary pulmonary hypertension, renal failure conditions, such as diabetic nephropathy, glomerulonephritis (including IgA nephropathy), renal fibrosis, scleroderma, glomerular sclerosis, proteinuria of renal disease, and also renal vascular hypertension, diabetic retinop

Abstract: The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof and at least one antidiabetic agent.

Abstract: A paving machine that is driven by track assemblies utilizing continuous rubber belts uses a motor and planetary gear reduction combination on each drive wheel to drive each belt. Each planetary gear includes a planetary joint connection between a rotating and a non-rotating portion, with an elastomeric seal therein to retain lubricating fluid in the planetary housing. Each drive wheel is formed from a pair of annular ring members rigidly connected together and spaced apart to provide a passage for directing debris falling from a rotating drive wheel away from the planetary joint, to minimize damage to the seal.

Abstract: A paving machine is driven by track assemblies utilizing continuous rubber belts driven by drive wheels. Each drive wheel is driven by a planetary gear assembly. Each drive wheel is formed from a pair of annular ring members rigidly connected together and spaced apart to provide a passage for directing debris falling from a rotating drive wheel away from the planetary gear, to minimize damage to the planetary gear assembly.

Abstract: A wall system for clean rooms employs an elongated framing member having four channels each with a thread slot in the bottom of the channel. This four channel arrangement facilitates the concealment of the fasteners and brackets used to join framing members to one another.